- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Recruiting • Phase III • Oncology • NCT06551324.
- What is being tested: PF-06821497 (mevrometostat), a novel investigational medicine, combined with enzalutamide versus standard treatments (enzalutamide alone or docetaxel chemotherapy) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously progressed on abiraterone acetate.
- Patient eligibility overview: The trial recruits men with mCRPC who have received prior abiraterone acetate treatment and are eligible for second-line therapy, comparing outcomes in a randomized, multi-centre design across participating UK healthcare centres.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
- : * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan. * Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required. * Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.